Incyte-linked ruxolitinib trials post results; both MGH and UT Southwestern studies report
Two Incyte-collaborator trials of ruxolitinib (Jakafi) posted results this week, covering transplant-related myelofibrosis outcomes and a small cancer cachexia pilot.
This week brought results postings for two ruxolitinib studies in which Incyte Corporation is a collaborator rather than lead sponsor.
- A Phase II trial led by Massachusetts General Hospital, which had actual primary completion on 2024-05-01 and study completion on 2025-05-19, posted results on 2026-07-09.1 The study assessed the efficacy and tolerability of ruxolitinib in myelofibrosis patients before, during and after hematopoietic stem cell transplantation, enrolling 44 participants.1
- A pilot study of ruxolitinib for cancer cachexia, sponsored by Tu Dan, is listed as active not recruiting, with actual primary completion on 2024-09-27 and estimated study completion in September 2026; results were first posted on 2026-07-07.2 The trial enrolled 10 participants in an early phase 1 design testing dose escalation in stage IV non-small cell lung cancer patients with cachexia.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.